Zentalis Pharmaceuticals
ZNTL
122 hedge funds and large institutions have $1.64B invested in Zentalis Pharmaceuticals in 2022 Q2 according to their latest regulatory filings, with 22 funds opening new positions, 55 increasing their positions, 31 reducing their positions, and 27 closing their positions.
8,929% more call options, than puts
Call options by funds: $1.53M | Put options by funds: $17K
77% more repeat investments, than reductions
Existing positions increased: 55 | Existing positions reduced: 31
6.62% more ownership
Funds ownership: 97.58% → 104.19% (+6.6%)
5% less funds holding
Funds holding: 129 → 122 (-7)
19% less first-time investments, than exits
New positions opened: 22 | Existing positions closed: 27
20% less capital invested
Capital invested by funds: $2.05B → $1.64B (-$415M)
25% less funds holding in top 10
Funds holding in top 10: 4 → 3 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MCMC
Matrix Capital Management Company
Portsmouth,
New Hampshire
|
+$128M |
| 2 |
DCMIC
Decheng Capital Management III (Cayman)
Grand Cayman,
Cayman Islands
|
+$48.3M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$33.2M |
| 4 |
Wellington Management Group
Boston,
Massachusetts
|
+$29M |
| 5 |
State Street
Boston,
Massachusetts
|
+$27.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$23.1M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
-$13.3M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
-$9.33M |
| 4 |
EC
EcoR1 Capital
San Francisco,
California
|
-$5.32M |
| 5 |
Renaissance Technologies
New York
|
-$5.04M |
ZNTL Hedge Fund Activity: Q2 2022 in Review
122 of the 5,959 institutional investors tracked by Wall St. Rank reported a position in Zentalis Pharmaceuticals (ZNTL) for Q2 2022, worth a combined $1.64B — down 20% from $2.05B a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of ZNTL and 22 opened new positions — a net loss of 5 holders — while 31 trimmed existing stakes and 55 added.
The largest buyer was Matrix Capital Management Company, adding an estimated $128M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $23.1M sold.
- 122 institutional investors held Zentalis Pharmaceuticals (ZNTL) as of Q2 2022, down from 129 in Q1 2022.
- Funds reported $1.64B of Zentalis Pharmaceuticals stock for Q2 2022, down 20% quarter-over-quarter.
- 22 funds opened new Zentalis Pharmaceuticals positions in Q2 2022 and 27 closed out, a net change of -5 holders.
- The largest Zentalis Pharmaceuticals buyer in Q2 2022 was Matrix Capital Management Company, an estimated $128M added.
- The largest Zentalis Pharmaceuticals seller in Q2 2022 was Perceptive Advisors, an estimated $23.1M sold.
Based on aggregated 13F filings for Q2 2022.